Abstract:Purpose: Bone tissue is constantly remodeled. Abnormal osteoclast formation may result in bone disorders, such as osteoporosis, Paget’s disease, and rheumatoid arthritis. Nuclear factor of κB (NF-κB) plays a key role in osteoclast formation and bone resorption. A key event in NF-κB signaling is the activation of an adaptor protein TRAF6. Once activated, TRAF6 further activates IKKβ (I-κB kinase), which phosphorylates I-κBα (the inhibitor of NF-κB), leading to its degradation. Carboxyl terminus of Hsp70-interacting protein (CHIP) is an E3 ligase and regulates the stability of several proteins which are involved in tumor growth and metastasis. However, the role of CHIP in bone remodeling in vivo has not been reported. The objective of this study is to investigate the role of CHIP in regulation of bone mass and bone remodeling and determine the molecular mechanism of CHIP in regulation of TRAF6 protein stability. Methods: The bone phenotype of 1-month-old Chip-/- mice was examined by histology, histomorphometry, μCT, and gene expression analyses. The regulation of CHIP on TRAF6 degradation and the inhibition of NF-κB signaling was examined by immunoprecipitation, Western blotting, and ubiquitination assay. Results: In this study, we found that deletion of Chip leads to osteopenic phenotype. There was significant reduction in bone volume (%, BV/TV, 66% decrease) and bone mineral density (59% decrease) in Chip-/- mice. Trabecular numbers (44% decrease), trabecular thickness (33% decrease) were significantly decreased in Chip-/- mice. In contrast, trabecular separation (1.7-fold increase) was significantly increased in Chip-/- mice. Higher structure model index (1.4-fold increase) and lower connectivity density (75% decrease) were observed in Chip-/- mice, suggesting more fragile bone when Chip gene is deleted. Cortical bone volume (40% decrease) and bone mineral density (40% decrease) were also significantly reduced in Chip-/- mice. One major reason for the osteopenic phenotype observed in Chip-/- mice could be due to the increase in osteoclast formation. TRAP-positive osteoclast numbers (1.6-fold increase) and osteoclast surface (1.5-fold increase) were significantly increased in Chip-/- mice. In vitro osteoclast formation assay showed that there was 3.5-fold increase in osteoclast formation in Chip-/- mice using osteoclast precursor cells isolated from WT and Chip-/- mice. Consistently bone resorption area was also increased in Chip-/- mice, demonstrated by an in vitro bone resorption assay using bone marrow cells derived from WT and Chip-/- mice. The expression of osteoclast marker genes, such as Cathepsin K (7-fold increase), Mmp9 (16-fold increase), Trap (16-fold increase), and Nfatc1 (3-fold increase), was significantly increased after RANKL treatment in bone marrow cells derived from Chip-/- mice. There was a significant increase in TRAF6 protein levels in Chip-deficient bone marrow cells. In contract, no changes in TRAF6 mRNA levels were found in the same Chip-/- cells, suggesting that CHIP may regulate TRAF6 protein stability. In a series of in vitro studies we found that: 1) Interaction of endogenous CHIP with TRAF6 was detected in RAW264.7 osteoclast-like cells. 2) The ubiquitination of endogenous TRAF6 protein was reduced in Chip-/- bone marrow cells. 3) The phosphorylation of IKKα/β and IκBα was significantly increased in Chip-/- bone marrow cells after RANKL stimulation. 4) p65 nuclear translocation was enhanced in Chip-/- bone marrow cells when the cells were treated with RANKL. Conclusions: Our studies demonstrated that CHIP interacts with TRAF6 in osteoclast precursor cells and promotes TRAF6 ubiquitination and proteasome degradation; subsequently inhibits NF-κB signaling and regulates osteoclast formation. In Chip KO mice TRAF6 protein levels are increased, leading to activation of osteoclast formation and significant bone loss.

TMBIM6 deficiency leads to bone loss by accelerating osteoclastogenesis

TMEM135 Maintains the Equilibrium of Osteogenesis and Adipogenesis by Regulating Mitochondrial Dynamics

TMBIM6 (transmembrane BAX inhibitor motif containing 6) enhances autophagy through regulation of lysosomal calcium

TMBIM6/BI-1 is an intracellular environmental regulator that induces paraptosis in cancer via ROS and Calcium-activated ERAD II pathways

TMEM175 plays a crucial role in osteoblast differentiation by regulating lysosomal function and autophagy

REGγ is Essential to Maintain Bone Homeostasis by Degrading TRAF6, Preventing Osteoporosis

Histological Evidence of Increased Osteoclast Cell Number and Asymmetric Bone Resorption Activity in the Tibiae of Interleukin-6-Deficient Mice

Unique expression and critical role of metallothionein 3 in the control of osteoclastogenesis and osteoporosis

WTAP-mediated m 6 A modification modulates bone marrow mesenchymal stem cells differentiation potential and osteoporosis

Defective Autophagy in Osteoblasts Induces Endoplasmic Reticulum Stress and Causes Remarkable Bone Loss

Histochemical Assessment of Accelerated Bone Remodeling and Reduced Mineralization in Il-6 Deficient Mice.

Chip is A Critical Regulator of Traf6 Degradation and Osteoclast Formation

WTAP-mediated m<SUP>6</SUP>A modification modulates bone marrow mesenchymal stem cells differentiation potential and osteoporosis

BAP1 promotes osteoclast function by metabolic reprogramming

Targeting TMBIM1 Alleviates Pathological Cardiac Hypertrophy.

SIRT6 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells Through BMP Signaling.

Crosstalk between BMPR1A deficiency and autophagy signaling mitigates pathological bone loss in osteoporosis

The Polycomb Protein Bmi1 Plays a Crucial Role in the Prevention of 1,25(OH)2 D Deficiency-Induced Bone Loss

Dysregulation of 5-hydroxytryptamine 6 receptor accelerates maturation of bone-resorbing osteoclasts and induces bone loss

INTS7-ABCD3 Interaction Stimulates the Proliferation and Osteoblastic Differentiation of Mouse Bone Marrow Mesenchymal Stem Cells by Suppressing Oxidative Stress

miR‐196b‐5p regulates osteoblast and osteoclast differentiation and bone homeostasis by targeting SEMA3A